This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
Hutchmed (China) Chairman Resigns, Successor Named MT
Hutchmed China Simon To leaves role, succeeded by Dan Eldar AN
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor MT
HUTCHMED Limited Announces Executive Changes CI
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress MT
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress CI
Transcript : HUTCHMED Limited Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies AN
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer MT
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China CI
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3% MT
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China MT
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui CI
HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024 CI
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer MT
Hutchmed to Present New Data at US Cancer Research Conference MT
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024 CI
Hutchmed endometrial cancer treatment application accepted for review AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination MT
HSBC in special payout on Canada sale; Astra FDA win AN
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status CI
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Chart HUTCHMED (China) Limited
More charts
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
3.773 USD
Average target price
5.651 USD
Spread / Average Target

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. News HUTCHMED (China) Limited
  5. Hutchmed Starts Bridging Study Follicular Lymphoma Treatment in China